03 July – Molecular Mechanisms of Targeted Cancer Treatments

Thursday 03 July, 2014, Christie Hospital, Manchester

1-day course: Molecular Mechanisms of Targeted Cancer Treatments

Level: Advanced/expert (Designed for doctors – from medical students to consultants – and senior oncology staff with a biological background. Ideal for junior doctors considering a future in oncology)

Description: This course covers a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. It also contains information on mechanisms of drug resistance to targeted agents and discusses the future of personalised cancer medicine.

To book, contact: education.events@christie.nhs.uk


Targeted cancer treatments: the current landscape
  • Where have we got to?
  • Hallmarks of cancer cells – choose your target
The main classes of current targeted treatments:
  • Monoclonal antibody (mAb) technology
  • Small molecule kinase inhibitors
Targeting cell communication pathways
  • Inhibitors of EGF-R and  HER2
  • PI3K,AKT & mTOR inhibitors
  • B-RAF & MEK inhibitors
More enzyme inhibitors
  • VEGFR/angiogenesis inhibitors
  • PARP inhibitors
  • ALK inhibitors
Practical exercise
Novel innovations to combat cancer
  • Epigenetic modifiers
  • HSP90 inhibitors
  • Immunotherapy
  • Hedgehog pathway inhibitors
Molecular and cellular mechanisms of drug resistance
  • Intrinsic and acquired drug resistance
  • Molecular mechanisms of drug resistance
  • The influence of intratumoural heterogeneity and the tumour microenvironment
Biomarkers and the personalisation of cancer treatment
  • Introduction to biomarkers
  • The use of biomarkers to select patients for trials and treatments for patients
  • The future of personalised cancer medicine